Alvogen
Setting a new standard for the future of pharma
Company
Who we are
Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 20 markets, Alvogen’s key regions include the U.S. and emerging markets in APAC regions.
Products
Targeted portfolio
Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars, brands and OTC products.
Robert Wessman
Meet our CEO
Robert Wessman‘s business plan for Alvogen was originally scribbled on a napkin in a New York restaurant back in 2009 in the middle of one of the worst financial crises in history when access to capital was virtually non-existent.
Newsroom
Latest news and initiatives
Follow news and programs from Alvogen around the world as they unfold.
Worldwide
Worldwide offices
Alvogen has commercial operations in 20 countries, including China, Hong Kong, Iceland, India, Luxembourg, Malaysia, Malta, USA, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, as well as regional hubs, manufacturing and R&D capabilities in the U.S. and South Korea.